Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

Castration Resistant ◽

Phase 2 Study ◽

Chemokine Ligand ◽

Cc Chemokine Ligand 2 ◽

Chemokine Ligand 2

A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a

Annals of Oncology ◽

10.1093/annonc/mdr336 ◽

2012 ◽

Vol 23 (1) ◽

pp. 53-58 ◽

Cited By ~ 24

Author(s):

K.N. Chi ◽

E. Beardsley ◽

B.J. Eigl ◽

P. Venner ◽

S.J. Hotte ◽

...

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Oncology Group ◽

Urologic Oncology ◽

Oncology Group Study ◽

Castration Resistant ◽

Phase 2 Study ◽

Previously Treated

Abstract LB-224: A randomized phase 2 study of two doses of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC)

10.1158/1538-7445.am2012-lb-224 ◽

2012 ◽

Author(s):

Emmanuel S. Antonarakis ◽

Elisabeth I. Heath ◽

David C. Smith ◽

Dana Rathkopf ◽

Amanda L. Blackford ◽

...

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Castration Resistant ◽

Phase 2 Study ◽

Randomized Phase 2

Abituzumab (Di17E6, Emd 525797) Treatment for Chemotherapy-Naive Patients with Asymptomatic or Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer (Mcrpc): Primary Outcomes of the Placebo-Controlled Phase 2 Study Perseus (Nct01360840)

Annals of Oncology ◽

10.1093/annonc/mdu336.20 ◽

2014 ◽

Vol 25 ◽

pp. iv266

Author(s):

K. Miller ◽

M. Hussain ◽

S. Le Moulec ◽

I. Rybicka ◽

R. Bruns ◽

...

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Castration Resistant ◽

Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors.

10.1200/jco.2010.28.15_suppl.2548 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 2548-2548 ◽

Cited By ~ 1

Author(s):

M. D. Forster ◽

A. Patnaik ◽

S. K. Sandhu ◽

K. Papadopoulos ◽

B. J. Tromp ◽

...

Keyword(s):

Clinical Trial ◽

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Human Monoclonal Antibody ◽

Final Analysis ◽

Advanced Solid Tumors ◽

Chemokine Ligand ◽

Cc Chemokine Ligand 2 ◽

Chemokine Ligand 2

Primary outcomes of the placebo-controlled phase 2 study PERSEUS (NCT01360840) investigating two dose regimens of abituzumab (DI17E6, EMD 525797) in the treatment of chemotherapy-naive patients (pts) with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC).

10.1200/jco.2014.32.15_suppl.5030 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5030-5030 ◽

Cited By ~ 2

Author(s):

Maha Hussain ◽

Kurt Miller ◽

Ilona Rybicka ◽

Rolf Bruns

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Castration Resistant ◽

A translational phase 2 study of cabozantinib in men with metastatic castration resistant prostate cancer with visceral metastases with characterization of circulating tumor cells and large oncosomes.

10.1200/jco.2014.32.15_suppl.e16080 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e16080-e16080

Author(s):

Edwin M. Posadas ◽

Mourad Tighgohart ◽

YI-TSUNG LU ◽

Dolores Di Vizio ◽

David M. J. Hoffman ◽

...

Keyword(s):

Prostate Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Phase 2 ◽

Castration Resistant ◽

Phase 2 Study ◽

Visceral Metastases

A randomized, double-blind phase 2 study of sipuleucel-T followed by indoximod or placebo in the treatment of patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.

10.1200/jco.2014.32.15_suppl.tps5111 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS5111-TPS5111

Author(s):

Gautam Gopalji Jha ◽

Jeffrey S Miller

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Double Blind ◽

Castration Resistant ◽

124 Activity and safety of the investigational agent orteronel (ortl, TAK-700) in men with nonmetastatic castration-resistant prostate cancer (CRPC) and rising prostate-specific antigen (PSA): Results of a phase 2 study

European Urology Supplements ◽

10.1016/s1569-9056(12)60123-7 ◽

2012 ◽

Vol 11 (1) ◽

pp. e124-e124a ◽

Cited By ~ 3

Author(s):

M. Hussain ◽

P. Corn ◽

D. Michaelson ◽

H. Hammers ◽

J. Alumkal ◽

...

Keyword(s):

Prostate Cancer ◽

Prostate Specific Antigen ◽

Specific Antigen ◽

Phase 2 ◽

Investigational Agent ◽

Castration Resistant ◽

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort

European Urology ◽

10.1016/j.eururo.2016.04.023 ◽

2016 ◽

Vol 70 (6) ◽

pp. 963-970 ◽

Cited By ~ 55

Author(s):

Matthew R. Smith ◽

Emmanuel S. Antonarakis ◽

Charles J. Ryan ◽

William R. Berry ◽

Neal D. Shore ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

High Risk ◽

Antitumor Activity ◽

Receptor Antagonist ◽

Phase 2 ◽

Androgen Receptor Antagonist ◽

Castration Resistant ◽

A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer

Investigational New Drugs ◽

10.1007/s10637-017-0553-x ◽

2017 ◽

Vol 36 (2) ◽

pp. 278-287 ◽

Cited By ~ 14

Author(s):

Evan Y. Yu ◽

Susan L. Ellard ◽

Sebastien J. Hotte ◽

Joel R. Gingerich ◽

Anthony M. Joshua ◽

...

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Castration Resistant ◽

Phase 2 Study ◽

Randomized Phase 2